Back
 OJRA  Vol.4 No.2 , May 2014
Clinical Phenotype of Japanese Patients with Dermatomyositis—Classification Based on Dermatomyositis-Specific Autoantibodies
Abstract: Objectives: To correlate the precise specificity of autoantibodies in Japanese dermatomyositis (DM) patients with their clinical phenotypes. Methods: Serum samples from 94 adult DM patients (67 with classical DM and 27 with clinically amyopathic dermatomyositis, CADM) were screened for autoantibodies using immunoprecipitation assays. Patients with antibodies against aminoacyl transfer RNA synthetase (ARS), Mi-2 or who had other autoantibodies were assessed for clinical symptoms and laboratory findings. Results: Sera from 27 of 94 DM patients (29%) were found to have anti-ARS antibodies. Nineteen (20%) had anti-CADM-140/MDA5, 5 (5%) had anti-Mi-2, and 8 (6%) had anti-p155/TIF1-γ. Anti-MJ/NXP-2 was not found in our series of adult DM. Seventeen patients with anti-ARS had fever and 22 had arthritis and interstitial lung disease (ILD), compatible with a diagnosis of anti-ARS syndrome. Seventeen of 19 (89%) with anti-CADM-140/MDA5 had ILD, 16 (84%) of whom developed rapidly progressive ILD (RP-ILD). Four of 5 (80%) with anti-Mi-2 had heliotrope rash and/or Gottron’s sign/papules, and 2 (40%) had V-sign and/or shawl-sign rash, whereas no ILD or malignancy was detected. As seen with anti-Mi-2-positive patients, a low frequency of ILD (13%) was found in patients with anti-p155/TIF1-γ but 6 of 8 (75%) had malignancy during their course. The frequency of ILD was significantly higher in patients with anti-ARS or anti-CADM-140/MDA5 compared with anti-Mi-2 or anti-p155/TIF1-γ (81% and 89%, respectively). It should be noted that anti-CADM-140/MDA5-positive patients suffered significantly more RP-ILD compared to patients with anti-ARS (84% vs. 7%, P < 0.0001). On the other hand, anti-p155/TIF1-γ positive patients had a significantly higher rate of malignancy compared with anti-ARS-, anti-CADM-140/MDA5-and anti-Mi-2-positive patients (75% vs. 7%: P = 0.0004, 5%: P = 0.0006, 0%: P = 0.02, respectively). Conclusions: These results indicate that in addition to antibodies previously identified as specific for DM, autoantibodies newly found in these patients are useful for stratifying them into clinical subgroups.
Cite this paper: Sato, S. , Kuwana, M. , Hirakata, M. , Nogi, S. , Sasaki, N. , Chinen, N. , Honda, K. , Saito, E. , Wakabayashi, T. , Yamada, C. and Suzuki, Y. (2014) Clinical Phenotype of Japanese Patients with Dermatomyositis—Classification Based on Dermatomyositis-Specific Autoantibodies. Open Journal of Rheumatology and Autoimmune Diseases, 4, 124-130. doi: 10.4236/ojra.2014.42018.
References

[1]   Targoff, I.N. (2004) Laboratory Testing in the Diagnosis and Management of Idiopathic Inflammatory Myopathies. Rheumatic Disease Clinics of North America, 28, 859-890.
http://dx.doi.org/10.1016/S0889-857X(02)00032-7

[2]   Mimori, T., Imura, Y., Nakashima, R. and Yoshifuji, H. (2007) Autoantibodies in Idiopathic Inflammatory Myopathy: An Update on Clinical and Pathophysiological Significance. Current Opinion in Rheumatology, 19, 523-529. http://dx.doi.org/10.1097/BOR.0b013e3282f01a8c

[3]   Targoff, I.N., Johnson, A.E. and Miller, F.W. (1990) Antibody to Signal Recognition Particle in Polymyositis. Arthritis & Rheumatology, 33, 1361-1370. http://dx.doi.org/10.1002/art.1780330908

[4]   Targoff, I.N. and Reichlin, M. (1985) The Association between Mi-2 Antibodies and Dermatomyositis. Arthritis & Rheumatology, 28, 796-803. http://dx.doi.org/10.1002/art.1780280711

[5]   Targoff, I.N., Mamyrova, G., Trieu, E.P., Perurena, O., Koneru, B., O’Hanlon, T.P., Miller, F.W. and Rider, L.G., Childhood Myositis Heterogeneity Study Group, International Myositis Collaborative Study Group (2006) A Novel Autoantibody to a 155-kd Protein Is Associated with Dermatomyositis. Arthritis & Rheumatology, 54, 3682-3689. http://dx.doi.org/10.1002/art.22164

[6]   Kaji, K., Fujimoto, M., Hasegawa, M., Kondo, M., Saito, Y., Komura, K., Matsushita, T., Orito, H., Hamaguchi, Y., Yanaba, K., Itoh, M., Asano, Y., Seishima, M., Ogawa, F., Sato, S. and Takehara, K. (2007) Identification of a Novel Autoantibody Reactive with 155 and 140 kDa Nuclear Proteins in Patients with Dermatomyositis: An Association with Malignancy. Rheumatology (Oxford), 46, 25-28. http://dx.doi.org/10.1093/rheumatology/kel161

[7]   Sato, S., Hirakata, M., Kuwana, M., Suwa, A., Inada, S., Mimori, T., Nishikawa, T., Oddis, C.V. and Ikeda, Y. (2005) Autoantibodies to a 140-kd Polypeptide, CADM-140, in Japanese Patients with Clinically Amyopathic Dermatomyositis. Arthritis & Rheumatology, 52, 1571-1576.
http://dx.doi.org/10.1002/art.21023

[8]   Sato, S., Hoshino, K., Satoh, T., Fujita, T., Kawakami, Y. and Kuwana M. (2009) RNA Helicase Encoded by Melanoma Differentiation-Associated Gene 5 Is a Major Autoantigen in Patients with Clinically Amyopathic Dermatomyositis: Association with Rapidly Progressive Interstitial Lung Disease. Arthritis & Rheumatology, 60, 2193-2200. http://dx.doi.org/10.1002/art.24621

[9]   Targoff, I.N. (1990) Autoantibodies to Aminoacyl-Transfer RNA Synthetases for Isoleucine and Glycine. Two additional synthetases are antigenic in myositis. The Journal of Immunology, 144, 1737-1743.

[10]   Hirakata, M., Mimori, T., Akizuki, M., Craft, J., Hardin, J.A. and Homma, M. (1992) Autoantibodies to Small Nuclear and Cytoplasmic Ribonucleoproteins in Japanese Patients with Inflammatory Muscle Disease. Arthritis & Rheumatology, 35, 449-456. http://dx.doi.org/10.1002/art.1780350415

[11]   Bohan, A. and Peter, J.B. (1975) Polymyositis and Dermatomyositis. The New England Journal of Medicine, 292, 344- 347. http://dx.doi.org/10.1056/NEJM197502132920706

[12]   Lane, R.J., Emslie-Smith, A., Mosquera, I.E. and Hudgson, P. (1989) Clinical, Biochemical and Histological Responses to Treatment in Polymyositis: A Prospective Study. Journal of the Royal Society of Medicine, 82, 333-338.

[13]   Sontheimer, R.D. (2002) Would a New Name Hasten the Acceptance of Amyopathic Dermatomyositis (Dermatomyositis Sine Myositis) as a Distinctive Subset within the Idiopathic Inflammatory Dermatomyopathies Spectrum of Clinical Illness? Journal of the American Academy of Dermatology, 46, 626-636. http://dx.doi.org/10.1067/mjd.2002.120621

[14]   Sato, S., Kuwana, M. and Hirakata, M. (2007) Clinical Characteristics of Japanese Patients with Anti-OJ (Anti-Isoleucyl-tRNAsynthetase) Autoantibodies. Rheumatology (Oxford), 46, 842-845.
http://dx.doi.org/10.1093/rheumatology/kel435

[15]   Hamaguchi, Y., Kuwana, M., Hoshino, K.,Hasegawa, M., Kaji, K., Matsushita, T., Komura, K., Nakamura, M., Kodera, M., Suga, N., Higashi, A., Ogusu, K., Tsutsui, K., Furusaki, A., Tanabe, H., Sasaoka, S., Muro, Y., Yoshikawa, M., Ishiguro, N., Ayano, M., Muroi, E., Fujikawa, K., Umeda, Y., Kawase, M., Mabuchi, E., Asano, Y., Sodemoto, K., Seishima, M., Yamada, H., Sato, S., Takehara, K. and Fujimoto, M. (2011) Clinical Correlations with Dermatomyositis-Specific Autoantibodies in adult Japanese Patients with Dermatomyositis: A Multicenter Cross-Sectional Study. Archives of Dermatology, 147, 391-398. http://dx.doi.org/10.1001/archdermatol.2011.52

[16]   Ikeda, N., Takahashi, K., Yamaguchi, Y., Inasaka, M., Kuwana, M. and Ikezawa, Z. (2011) Analysis of Dermatomyositis-Specific Autoantibodies and Clinical Characteristics in Japanese Patients. The Journal of Dermatology, 38, 973-979. http://dx.doi.org/10.1111/j.1346-8138.2011.01262.x

 
 
Top